128 related articles for article (PubMed ID: 38270613)
1. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
Cancer Chemother Pharmacol; 2024 May; 93(5):439-453. PubMed ID: 38270613
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
3. Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
Lin S; Ionescu A; Maynard-Scott J; Kennedy M; Walling DP; Furey M; Singh JB
Clin Transl Sci; 2024 May; 17(5):e13791. PubMed ID: 38700236
[TBL] [Abstract][Full Text] [Related]
4. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
[TBL] [Abstract][Full Text] [Related]
5. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
Davis J; Langdon G; Layton G; Chong CL; Ndongo MN; Vourvahis M
Eur J Clin Pharmacol; 2012 Nov; 68(11):1567-72. PubMed ID: 22527351
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Gu H; Dutreix C; Rebello S; Ouatas T; Wang L; Chun DY; Einolf HJ; He H
Drug Metab Dispos; 2018 Feb; 46(2):109-121. PubMed ID: 29117990
[TBL] [Abstract][Full Text] [Related]
7. Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
Dennison J; Puri A; Warrington S; Endo T; Adeloye T; Johnston A
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):860-870. PubMed ID: 29870591
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Wang X; Dowty ME; Tripathy S; Le VH; Huh Y; Curto M; Winton JA; O'Gorman MT; Chan G; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):367-381. PubMed ID: 38554232
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.
Palovaara S; Pelkonen O; Uusitalo J; Lundgren S; Laine K
Clin Pharmacol Ther; 2003 Oct; 74(4):326-33. PubMed ID: 14534519
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
[TBL] [Abstract][Full Text] [Related]
11. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
[TBL] [Abstract][Full Text] [Related]
12. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
13. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
Wiesinger H; Klein S; Rottmann A; Nowotny B; Riecke K; Gashaw I; Brudny-Klöppel M; Fricke R; Höchel J; Friedrich C
Clin Pharmacol Ther; 2020 Oct; 108(4):798-807. PubMed ID: 32275771
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Filppula AM; Mustonen TM; Backman JT
Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
[TBL] [Abstract][Full Text] [Related]
17. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello W; Rosenkranz B; Schmid B; Wierich W
Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants.
Hoch M; Sengupta T; Hourcade-Potelleret F
Clin Transl Sci; 2022 Jun; 15(6):1406-1416. PubMed ID: 35293131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
